πŸ›οΈ Verified NIH Record β€’ Updated 2026-04-20

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer (NCT06157151)

A Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer.

🟒 Recruiting Phase2 πŸ’Š Investigational Drug / Biologic Sponsor: Precigen, Inc

🩺 Plain-English Summary (8th-Grade Level)

This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.

Who can join: Review the eligibility criteria below.

Location: University of Arkansas for Medical Sciences β€” Little Rock, Arkansas

Age range: 18 Years

πŸ§ͺ Interventions in This Study

πŸ“‹ "Do I Qualify?" β€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria β†—

πŸ“ All Participating Trial Locations (3 Sites)

  • University of Arkansas for Medical Sciences β€” Little Rock, Arkansas
  • National Institute of Health β€” Bethesda, Maryland
  • University of Washington β€” Seattle, Washington

πŸ“ž Contact the Study Coordinator

Phone: (301) 556-9900

Email: clinicaltrials@precigen.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

πŸ’° Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Cervical Cancer clinical trials

πŸ’‘ How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
πŸ›οΈ View Official NIH Record β†—